| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
Departments of 1 Microbiology and Molecular Genetics and 2 Biological Chemistry and Developmental and Cell Biology, College of Medicine, University of California, Irvine, California; and Departments of 3 System Biology and 4 Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
Requests for reprints: Eric J. Stanbridge, Department of Microbiology and Molecular Genetics, College of Medicine, University of California, Irvine, CA 92697. Phone: 949-824-7042; Fax: 949-824-2454; E-mail: ejstanbr{at}uci.edu, or Eva Y-H. P. Lee, Departments of Biological Chemistry and Developmental and Cell Biology, College of Medicine, University of California, Irvine, CA 92697. Phone: 949-824-9766; Fax: 949-824-9767; E-mail: elee{at}uci.edu.
Key Words: BRCA1 DNA repair breast cancer cancer stem cells chemoresistance
The majority of BRCA1-associated breast cancers are basal cell–like, which is associated with a poor outcome. Using a spontaneous mouse mammary tumor model, we show that platinum compounds, which generate DNA breaks during the repair process, are more effective than doxorubicin in Brca1/p53–mutated tumors. At 0.5 mg/kg of daily cisplatin treatment, 80% primary tumors (n = 8) show complete pathologic response. At greater dosages, 100% show complete response (n = 19). However, after 2 to 3 months of complete remission following platinum treatment, tumors relapse and become refractory to successive rounds of treatment. Approximately 3.8% to 8.0% (mean, 5.9%) of tumor cells express the normal mammary stem cell markers, CD29hi24med, and these cells are tumorigenic, whereas CD29med24–/lo and CD29med24hi cells have diminished tumorigenicity or are nontumorigenic, respectively. In partially platinum-responsive primary transplants, 6.6% to 11.0% (mean, 8.8%) tumor cells are CD29hi24med; these populations significantly increase to 16.5% to 29.2% (mean, 22.8%; P < 0.05) in platinum-refractory secondary tumor transplants. Further, refractory tumor cells have greater colony-forming ability than the primary transplant–derived cells in the presence of cisplatin. Expression of a normal stem cell marker, Nanog, is decreased in the CD29hi24med populations in the secondary transplants. Top2A expression is also down-regulated in secondary drug-resistant tumor populations and, in one case, was accompanied by genomic deletion of Top2A. These studies identify distinct cancer cell populations for therapeutic targeting in breast cancer and implicate clonal evolution and expansion of cancer stem-like cells as a potential cause of chemoresistance. [Cancer Res 2008;68(9):3243–50]
This article has been cited by other articles:
![]() |
F. Muggia BRCA-deficient animal models and cisplatin resistance Ann. Onc., May 1, 2009; 20(5): 962 - 962. [Full Text] [PDF] |
||||
![]() |
J. Fasano and F. Muggia Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development Ann. Onc., April 1, 2009; 20(4): 609 - 614. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Magnifico, L. Albano, S. Campaner, D. Delia, F. Castiglioni, P. Gasparini, G. Sozzi, E. Fontanella, S. Menard, and E. Tagliabue Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab Clin. Cancer Res., March 15, 2009; 15(6): 2010 - 2021. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Korkaya and M. S. Wicha HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of Evil Clin. Cancer Res., March 15, 2009; 15(6): 1845 - 1847. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Luo, H. Fan, T. Nagy, H. Wei, C. Wang, S. Liu, M. S. Wicha, and J.-L. Guan Mammary Epithelial-Specific Ablation of the Focal Adhesion Kinase Suppresses Mammary Tumorigenesis by Affecting Mammary Cancer Stem/Progenitor Cells Cancer Res., January 15, 2009; 69(2): 466 - 474. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Vaillant, M.-L. Asselin-Labat, M. Shackleton, N. C. Forrest, G. J. Lindeman, and J. E. Visvader The Mammary Progenitor Marker CD61/{beta}3 Integrin Identifies Cancer Stem Cells in Mouse Models of Mammary Tumorigenesis Cancer Res., October 1, 2008; 68(19): 7711 - 7717. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |